https://nsc190940inhibitor.com..../usage-of-diabetes-r
The therapy arms got either three rounds of 5-fluorouracil, epirubicin, and cyclophosphamide, accompanied by three cycles of docetaxel (FEC → Doc); or three rounds of FEC accompanied by three cycles of docetaxel and gemcitabine (FEC → Doc/Gem). The main study aim had been disease-free survival (DFS), and also the primary additional goals were overall success (OS) and safety. No differences were observed in the 5-year DFS or OS between FEC → Doc and FEC → Doc/Gem. The threat ratio had be
Curtir
Comentario
Compartilhar
